Pharmaceuticals Japan

Japan Precision Oncology Market Analysis, 2024–2034

Japan Precision Oncology Market Industry Trends and Forecast to 2034: Segmented by (Product, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $7.34 Bn Estimated value
Estimate 2025 $8.11 Bn 7.1% of the global market
Projected 2034 $19.92 Bn 145.6% Adds $11.81 Bn over 9 forecast years
CAGR 2025–2034 10.5% Faster than 61% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 7.05% of the global market.
  • In APAC, the largest is China at $10.57 Bn.
  • Fastest growing: India at 12.8% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$11.81 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Precision Oncology Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $7.34 Bn — —
2025 (base) $8.11 Bn +$770.5 Mn —
2026 (forecast) $8.96 Bn +$851.4 Mn +10.5%
2027 (forecast) $9.90 Bn +$940.8 Mn +22.1%
2028 (forecast) $10.94 Bn +$1.04 Bn +34.9%
2029 (forecast) $12.09 Bn +$1.15 Bn +49.1%
2030 (forecast) $13.36 Bn +$1.27 Bn +64.7%
2031 (forecast) $14.76 Bn +$1.40 Bn +82%
2032 (forecast) $16.31 Bn +$1.55 Bn +101.2%
2033 (forecast) $18.02 Bn +$1.71 Bn +122.3%
2034 (forecast) $19.92 Bn +$1.89 Bn +145.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

The Japan Precision Oncology Market Analysis Executive Summary

Precision oncology matches cancer treatment to the genetic changes in a patient's tumour, using tests and targeted drugs.

Key segments of the precision Oncology market include product (Genomic Tests, Targeted Therapies and Informatics Platforms) and cancer (Lung, Breast and Colorectal).

Japan Precision Oncology Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the precision Oncology market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the precision Oncology market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the precision Oncology market, especially in low- and middle-income countries.

Competitive Landscape for Precision Oncology Market in Japan

The precision Oncology market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Precision Oncology Market in Japan

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for precision Oncology. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Precision Oncology right now, from free public sources.

Clinical trials

1 active trial in Japan

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Tempus 5 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Orca Biosystems, Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Precision Oncology in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on Precision Oncology are running in Japan?
1 study is recruiting, active or about to start in Japan.[4]
How much research is published on Precision Oncology?
PubMed lists 7,542 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Back to Catalogue

Related Pharmaceuticals reports in Japan

See all

Related on oncology and genomics

See the topic